Skip to main content
. 2022 Dec 1;17(12):e0266584. doi: 10.1371/journal.pone.0266584

Table 2. Results.

Patients Seropositivity against
COVID spike protein		 p-value; UVA OR (95% CI), p-value; MVA OR (95% CI), p-value
Primary vaccination series
no. of events/ total no. (%)		 Additional primary shot†
no. of events/ total no. (%)
Overall population 158/243 (65) 38/46 (83)
Timing of last anticancer treatment
    None (ref)
    Within the last 6 months
    More than 6 months
30/46 (65)
45/92 (49)
83/105 (79)
9/9 (100)
20/24 (83)
9/13 (69)		 <0.001;
0.51 (0.24, 1.06), p = 0.072,
2.01 (0.93, 4.33), p = 0.074;
0.52 (0.22, 1.23), p = 0.14,
1.16 (0.43, 3.08), p = 0.77
Timing of anti-CD20 monoclonal antibody
    None (ref)
    Received rituximab in past 12 months
    Received rituximab ≥12 months
91/144 (63)
21/45 (47)
46/54 (85)
29/32 (91)
4/7 (57)
5/7 (71)		 <0.001;
0.51 (0.26, 1.00), p = 0.05, 3.35 (1.47, 7.63), p = 0.004;
0.62 (0.27, 1.42), p = 0.26,
2.38 (0.85, 6.70), p = 0.10
Timing of IVIG
    Received no IVIG. (ref)
    Received IVIG previous 6 months
145/213 (68)
13/30 (43)
31/38 (82)
7/8 (88)		 0.014;
0.36 (0.16, 0.78), p = 0.01;
0.39 (0.17, 0.93), p = 0.03
Disease type
    CLL/SLL (ref)
    Burkitt’s, DLBCL, PMBL
    HL/TCL‡
    Indolent lymphomas§
    MCL
    Other
42/56 (75)
28/55 (51)
34/44 (77)
44/72 (61)
6/12 (50)
4/4 (100)
11/12 (92)
10/10 (100)
3/3 (100)
9/15 (60)
4/5 (80)
1/1 (100)		 0.016;
2.89 (1.30, 6.46), p = 0.01; 2.71 (1.04, 7.06), p = 0.04.
3.27 (1.39, 7.91), p = 0.01;
3.29 (1.25, 8.64), p = 0.02.
1.52 (0.75, 3.81), p = 0.25;
1.41 (0.62, 3.20), p = 0.42.
0.96 (0.27, 3.36), p = 0. 95;
1.29 (0.33, 5.03), p = 0.71.
Inf, p = 0.98; Inf, p = 0.98
History of COVID infection
    Negative (ref)
    Positive
139/216 (64)
19/24 (79)
37/45 (82)
1/1 (100)
 0.09;
2.6 (0.8, 7.8), p = 0.1; 3.1 (1, 9.9), p = 0.06

†In patients with resulted anti-COVID spike protein antibody levels.

‡Includes peripheral T-cell lymphomas not otherwise specified (NOS), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphomas, angioimmunoblastic T-cell lymphoma (AITL), and acute T-cell leukemia/lymphoma (ATLL).

§Includes follicular lymphomas, marginal zone lymphoma, lymphoplasmacytic lymphoma, and Waldenstrom macroglobulinemia.

Include monoclonal gammopathy of undetermined significance (MGUS), T-cell prolymphocytic leukemia (T-PLL), Essential thrombocytosis, and primary CNS lymphoma.

DLBCL = diffuse large B-cell lymphoma; PMBL = primary mediastinal B-cell lymphoma; CLL = chronic lymphocytic leukemia; SLL = small lymphocytic lymphoma; HL = Hodgkin lymphomas; TCL = T-cell lymphomas; MCL = mantle cell lymphoma; IVIG = intravenous immune globulin.